|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:azidothymidine_(AZT)
|
|
gptkbp:activities
|
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
Zerit
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
HIV treatment regimen
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe liver disease
pancreatitis
hypersensitivity to stavudine
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
gptkb:1980s
|
|
gptkbp:formulation
|
gptkb:beer
suspension
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
stavudine
|
|
gptkbp:ingredients
|
C10 H12 N2 O4
|
|
gptkbp:interacts_with
|
gptkb:didanosine
gptkb:lamivudine
gptkb:zidovudine
|
|
gptkbp:invention
|
gptkb:2001
patented
|
|
gptkbp:is_atype_of
|
J05 A F03
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_used_for
|
treatment of HIV/ AIDS
|
|
gptkbp:lifespan
|
1.5 hours
|
|
gptkbp:marketed_as
|
Zerit
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
gptkb:battle
oral bioavailability 86%
|
|
gptkbp:side_effect
|
gptkb:lipodystrophy
fatigue
headache
nausea
diarrhea
lactic acidosis
neuropathy
|
|
gptkbp:treatment
|
HIV infection
|
|
gptkbp:type_of
|
30516-87-1
|